116 related articles for article (PubMed ID: 14968900)
1. Systemic side effects of ophthalmic drops.
Levy Y; Zadok D
Clin Pediatr (Phila); 2004; 43(1):99-101. PubMed ID: 14968900
[TBL] [Abstract][Full Text] [Related]
2. Is brimonidine ophthalmic a safe therapy for infants?
Daubert GP
J Clin Pharm Ther; 2006 Jun; 31(3):289-92. PubMed ID: 16789995
[TBL] [Abstract][Full Text] [Related]
3. Hypotension and bradycardia in infants after the use of topical brimonidine and beta-blockers.
Mungan NK; Wilson TW; Nischal KK; Koren G; Levin AV
J AAPOS; 2003 Feb; 7(1):69-70. PubMed ID: 12690374
[TBL] [Abstract][Full Text] [Related]
4. Ocular and systemic side effects of brimonidine 0.2% eye drops (Alphagan) in children.
Bowman RJ; Cope J; Nischal KK
Eye (Lond); 2004 Jan; 18(1):24-6. PubMed ID: 14707960
[TBL] [Abstract][Full Text] [Related]
5. Reversible cicatricial ectropion precipitated by topical brimonidine eye drops.
Aristodemou P; Baer R
Ophthalmic Plast Reconstr Surg; 2008; 24(1):57-8. PubMed ID: 18209648
[TBL] [Abstract][Full Text] [Related]
6. Selectivity of site of action and systemic effects of topical alpha agonists.
Robin AL; Burnstein Y
Curr Opin Ophthalmol; 1998 Apr; 9(2):30-3. PubMed ID: 10180510
[TBL] [Abstract][Full Text] [Related]
7. Apparent central nervous system depression in infants after the use of topical brimonidine.
Carlsen JO; Zabriskie NA; Kwon YH; Barbe ME; Scott WE
Am J Ophthalmol; 1999 Aug; 128(2):255-6. PubMed ID: 10458196
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of glaucoma with brimonidine (Alphagan 0.2%)].
Detry-Morel M; Dutrieux C
J Fr Ophtalmol; 2000 Oct; 23(8):763-8. PubMed ID: 11033496
[TBL] [Abstract][Full Text] [Related]
9. Demographic and clinical factors associated with development of brimonidine tartrate 0.2%-induced ocular allergy.
Manni G; Centofanti M; Sacchetti M; Oddone F; Bonini S; Parravano M; Bucci MG
J Glaucoma; 2004 Apr; 13(2):163-7. PubMed ID: 15097264
[TBL] [Abstract][Full Text] [Related]
10. Systemic adverse effects of topical treatment with brimonidine in an infant with secondary glaucoma.
Korsch E; Grote A; Seybold M; Soditt V
Eur J Pediatr; 1999 Aug; 158(8):685. PubMed ID: 10445353
[No Abstract] [Full Text] [Related]
11. Brimonidine hypersensitivity when switching between 0.2% and 0.15% formulations.
Sullivan-Mee M; Pensyl D; Alldredge B; Halverson K; Gerhardt G; Qualls C
J Ocul Pharmacol Ther; 2010 Aug; 26(4):355-60. PubMed ID: 20653479
[TBL] [Abstract][Full Text] [Related]
12. Brimonidine: a new alpha2-adrenoreceptor agonist for glaucoma treatment.
Greenfield DS; Liebmann JM; Ritch R
J Glaucoma; 1997 Aug; 6(4):250-8. PubMed ID: 9264305
[TBL] [Abstract][Full Text] [Related]
13. Brimonidine and pupillary diameter.
Mastropasqua L; Carpineto P; Ciancaglini M
Ophthalmology; 1998 Aug; 105(8):1352-3. PubMed ID: 9709738
[No Abstract] [Full Text] [Related]
14. Charles Bonnet syndrome precipitated by brimonidine tartrate eye drops.
Tomsak RL; Zaret CR; Weidenthal D
Br J Ophthalmol; 2003 Jul; 87(7):917. PubMed ID: 12812898
[No Abstract] [Full Text] [Related]
15. Anterior uveitis as a side effect of topical brimonidine.
Byles DB; Frith P; Salmon JF
Am J Ophthalmol; 2000 Sep; 130(3):287-91. PubMed ID: 11020406
[TBL] [Abstract][Full Text] [Related]
16. Exposure to topical apraclonidine in children with glaucoma.
Wright TM; Freedman SF
J Glaucoma; 2009; 18(5):395-8. PubMed ID: 19525731
[TBL] [Abstract][Full Text] [Related]
17. Side-effect profile of brimonidine tartrate in children.
Al-Shahwan S; Al-Torbak AA; Turkmani S; Al-Omran M; Al-Jadaan I; Edward DP
Ophthalmology; 2005 Dec; 112(12):2143. PubMed ID: 16225927
[TBL] [Abstract][Full Text] [Related]
18. Does topical brimonidine tartrate help NAION?
Fazzone HE; Kupersmith MJ; Leibmann J
Br J Ophthalmol; 2003 Sep; 87(9):1193-4. PubMed ID: 12928304
[No Abstract] [Full Text] [Related]
19. Update in glaucoma: the new pharmacotherapies. Brimonidine versus apraclonidine.
Crichton AC
Can J Ophthalmol; 1998 Aug; 33(5):254-5; discussion 257-8. PubMed ID: 9740952
[No Abstract] [Full Text] [Related]
20. Effect of 0.2% brimonidine on retinal blood flow.
Yu M; Li Y; Liu X; Ling Y; Zheng X
Yan Ke Xue Bao; 2001 Mar; 17(1):42-5. PubMed ID: 12567595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]